Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Amgen (NasdaqGS:AMGN) and Kyowa Kirin have stopped all clinical trials of rocatinlimab after newly identified safety concerns. The companies cited potential links between OX40 pathway modulation and malignancies as the reason for the halt. The decision affects ongoing studies in multiple indications and removes a late stage candidate from Amgen's R&D pipeline. For a company like Amgen, which focuses on biologic therapies for serious diseases, the loss of a late stage asset such as rocatinlimab is meaningful for its research mix. It also comes at a time when large biopharma peers are working to refresh product portfolios as older drugs face competition and evolving treatment standards. Readers tracking biotech can view this as part of a broader pattern in which safety signals reshape portfolios even for well resourced players. Looking ahead, investors may pay cl
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Podcast: Sanofi's head of clinical supply chain operations on evolving the clinical trial supply model [Yahoo! Finance]Yahoo! Finance
- Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent directorGlobeNewswire
- Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/4/26 - Form 6-K
- 3/3/26 - Form 6-K
- 2/23/26 - Form 6-K
- SNY's page on the SEC website